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Biotechnology is coming of age, after many years of work on the regulatory
process and policies, as well as public awareness, educational issues, and
intellectual property. We are now recognizing that we need to assess every new
tool we use or product we develop to ensure human survival. Sustainability,
food security, health, and safety have become our goals for tomorrow.
This paper considers challenged environments from a variety of perspectives
of which the industry must always be cognizant — from the natural
environment to the business environment. Three key messages should be kept
in mind. First, biotechnology is a tool with which to develop new products —
not an end in and of itself. It offers a range of products that can address some
challenges, as well as offering novel options and value-added products not
previously available to producers, the processing/manufacturing industry, and
the consumer. The race to take advantage of this tool is on around the world,
and Canada now enjoys a leadership position. The initial products are here, and
whether we are users of this technology or not, we will be consumers of
imported products using the technology. The choice is ours as to whether we
will benefit.
The second important message is that partnerships are important to the
industry and to other stakeholders. Industry is continually forming strategic
alliances, either among companies or between the research community and
companies, in ways that are mutually advantageous. Each offers a strength that
the other lacks. The same is true for the community at large. We need to listen
to each other and work together as a whole, rather than as divided factions on
different missions. Forums such as this should be looked at as opportunities to
accomplish this goal and to learn what others are doing.
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The third message deals with recognition, learned the hard way, that no
single magic bullet exists. All new technologies or approaches we try have to be
used in the context of long-term sustainability. To accomplish this, we need to
look at the entire system and understand the effects of technology while we
trying to achieve our goals.
This paper deals with challenges from the industry point of view, recognizing
that no perspective exists in isolation. Each perspective must include others
when addressing these challenges. For this reason, while industry is a
developer, manufacturer, and user of tools of biotechnology, it would never stay
in business unless these products meet environmental, consumer, and
community needs. Industry also has an opportunity to become more
competitive via responsible use of biotechnology in traditional sectors. On the
other side of the coin, Canadians would have fewer jobs if the biotechnology
industry left Canada — but we would still be users of this technology because
other countries would be exporting their products to Canada. We would fall
behind competitively and economically. It is in this context that the challenges
are a matter of perception. The reality is that everyone must deal with the same
set of challenges.
We must ensure that sufficient, high-quality food can be produced while also
enabling agricultural producers to make a living in a way that is
environmentally sustainable over the long term. Consumers are concerned
about food security, safety, nutrition, and quality. To ensure long-term survival,
the industry must ensure that products developed will satisfy all these needs.
Finally, all members of the community must listen to each other and develop
ways to work together to help make these things happen.
I would like to address this technology from the standpoint of the
opportunities as well as issues. In its most global perspective, biotechnology
promises to meet challenges of several major sectors. In the health care sector,
new drugs will cure chronic, intractable, and often fatal diseases such as cancer,
AIDS, and osteoporosis. Compared to its world market share, Canada has a
disproportionate percentage of biotechnology health-care products. The
potential to develop more nutritious, healthier, high-quality foods and ways to
produce those foods clearly benefit agriculture. Animals and fish also can
benefit in many ways, such as improved health because of resistance to diseases
and infections. Environmental applications include products used for
bioremediation — cleaning up the environment using biological systems. In
forestry, potential products will be trees with resistance to both disease and
insects as well as the ability to grow faster. And finally, biotechnology shows
promise for bio-leaching in the area of mining.
These benefits can also be realized throughout the value chain. The producer
has access to more efficient, low-cost production methods that can also be more
sustainable than those available in the past. Processors may be able to process
more food products through the use of purer, lower-cost alternatives such as
transgenic chymosin to replace renin for cheese-making. Foods are becoming
more nutritious, safer, and lower cost. What can this technology offer us as
Canadians? We are leading in the development of these new products, and we
can reap the benefits in terms of global competitiveness and its advantages for
our economy. On an individual basis, this translates into a high standard of
living, and more jobs from a healthy economy. This is where the developers of
these products are important. These products will be useful not only to
Canadians but to our export markets.
The biotechnology industry in Canada has developed over 20 years and is
now enjoying a period of tremendous investment. Approximately 530
companies employing 23,000 Canadians use biotechnology as the main part or
as a portion of their business. In 1996, $1.7 billion was invested in research and
development, and annual revenues now exceed $3.5 billion. In addition, most
of the companies are small and medium-sized, not multinational, as is the
common perception. The industry is based on knowledge, innovation, and
research.
The industry still faces scientific challenges. This is a challenging technology,
and the science is still in its infancy in terms of understanding what genes code
for which traits, locating and transferring genetic material from one organism to
another, and finally expressing the genetic material in the intended organism.
The industry still needs to ensure that its new products meet a variety of needs,
including those of the business sector, the stakeholders, and the environment
— not an easy task. In addition, there are cultural differences between scientists
at universities and in industry and between the different sectors. As an example,
the culture is very different in the pharmaceutical industry than in the
agricultural industry. Public awareness issues and education are everyone’s
responsibility and industry is no exception. The industry is also faced with a
shortage of highly skilled people needed to meet the growing demand for in the
near term for scientists and managers. Regulations and policy will always be a
challenge. Wherever possible, countries should strive to harmonize their
regulatory requirements and approaches. Canada must provide a competitive
regulatory environment and ensure these issues are addressed in both national
and international ways.
I will highlight two of these issues — human resources and regulations
policy. A report entitled Building Long Term Capability Now projected 8,000 new
biotechnology jobs by the year 2000. Canada does not have the skills base to
meet this demand. The experience or skills gap is in the following areas:
• Basic and applied research
• Technology development
• Product/process development
• Marketing and sales
• Management
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The Biotechnology Human Resources Council (BHRC) has been established,
with support from the Human Resources Department of Canada, to help
develop people with the necessary expertise. The International Biotechnology
Association of Canada (IBAC) will manage the day-to-day operations of this
council, and an executive director will implement directions set by the BHRC
Board of Directors. Meeting these needs will require partnerships with
academia, government, and other organizations to develop training programs
and consider immigration policies.
Industry is working to establish policies regarding food labeling, intellectual
property protection, and biosafety. IBAC released a position paper at the
international CODEX Alimentarius meetings, held last month, that looked at
the various options available and their relative impacts. Small and medium-
sized businesses depend on outside financing, and the high costs of this new
area include that of intellectual property. Protecting assets through patents also
provides the opportunity to exchange scientific information. In the area of
biosafety, an international protocol for living modified organisms is under
development that will mean that products cannot be imported or exported
without prior notification and approval. It is anticipated that this protocol will
be in effect by January 1999.
The community has taken key steps to start meeting today’s challenges in
biotechnology. National and regional biotechnology organizations have
developed and agreed to the Biotechnology Accord, which provides working
principles for cooperation and partnerships throughout the community. We are
in the initial stages of implementing this accord and still need to define how we
can best use it to coordinate our activities. An issues/crisis management team
approach is being established to respond to issues as they arise. This will allow
various members of the community to share information and to provide similar
messages when necessary. Finally, the Food Biotechnology Communications
Network is leading the development of a national communications strategy that
should help coordinate various activities.
We still have some challenges to address. There are a significant number of
representative organizations to coordinate, and we need to become more
efficient in dealing with issues without duplication. The national organizations
are focusing on this problem. Specifically, IBAC and the Canadian Institute of
Biotechnology may merge into a single organization over the next two years. In
addition, there are numerous activities under development across Canada that
might be adopted or augmented. We need to consider how we can work with
organizations initiating new activities. The NABC should be looking for such
partnerships.
Finally, what is IBAC? We are a not-for-profit organization that was
established in 1987 to represent the biotechnology industry. We have dealt with
regulatory and policy issues in an advocacy role. We are now undergoing an
evolutionary process that embraces “reasoned advocacy.” Although regulatory
and policy issues will always be a part of our mandate, we now embrace human
resources, a much stronger communications role, support of research, and
financial considerations. We are committed to facilitating a supportive
environment for research and development as well as the commercialization of
new products in Canada.
In conclusion, biotechnology has become an important tool that offers new
alternatives to various sectors and stakeholder groups, from the producer to the
consumer. It has helped place Canada in a strong competitive position
internationally. As the use of this technology moves forward, we need to look
for more ways to work together, for a variety of reasons, including the effective
use of our resources to develop consistent messages. We need to tackle today’s
problems using a systems approach with sustainability and integration as our
priorities.
Biotechnology is an important tool that can help develop alternatives in our
move to more sustainable practices. To guarantee that Canadians have access to
the responsible use of these alternatives, we need to work together to ensure
that issues are dealt with and questions are answered. Finally, we need to ensure
that biotechnology, like any new tool, is based on our understanding of whole
systems rather than their parts. Challenges from different perspectives need to
be addressed, ranging from what can be done scientifically in the development
of new products for various users to what is needed. Other challenges include
meeting human resource requirements, differences among the various use
sectors, and, perhaps most important, public awareness.
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